© Redbow Consulting Group 2026, All rights reserved Conclusion: Synthesising Ambition, Pragmatism, and Human - Centricity for AI in Pharma The multifaceted interviews and synthesis presented illuminate a nuanced maturity continuum for AI adoption in pharmaceutical commercial functions. Leadership commitment and cultural framing emerge as the most potent levers in transcending both organisatio nal and technological barriers. The leader interviews strongly suggest that AI’s optimal value does not come from wholesale disruption, but from positioning it as an augmentation tool that enhances human expertise and decision - making. “It’s the combination of human plus AI... not AI alone — that’s the key.” This human - centric orientation necessitates ongoing, practical literacy programmes, empathetic change management, and trust - building measures. Without addressing employee fears and fostering cultural acceptance, AI risks being relegated to fragmented pilot s and voluntary usage patterns, limiting impact to modest efficiency gains rather than transformational improvements. S trong governance frameworks remain foundational yet vexing challenges , and b alancing innovation with risk management is an enduring tension. W hilst legal and compliance functions appropriately guard against regulatory and reputational risks, excessive conservatism or inconsistent governance can stifle scalable AI deployment. Cross - functional governance bodies that co - create clear guardrails and phase d rollouts are essential to safely accelerate adoption. The concomitant growth of shadow AI usage reflects systemic gaps in governance agility and digital enablement within organisations. I nconsistent data quality currently throttle s AI scalability , where f ragmented taxonomies and un - coded data persist . This work in progress leaves some organisations very early in the journey towards an AI - usable data set. Without this foundational work AI adoption cannot be truly transformative. Within the workforce, AI - driven efficiencies have already begun to reshape traditional roles, especially entry - level and front - line positions. A forward - looking talent strategy that incorporates AI skills alongside mentorship and experiential learning is critica l to sustaining organisational knowledge and creat es resilient career pathways. Change management programmes based on proven principles must be embedded to ensure both cultural normali s ation and behavioural adoption. Externally, the AI ecosystem is rapidly transforming market dynamics. Pharmaceutical companies must develop new competencies in generative AI optimisation and agility to navigate evolving customer behaviours and competitive landscapes. The ability to learn and adapt swiftly has become a more vital competitive differentiator than static excellence. In summary, the journey towards agentic AI maturity in pharma is neither purely technical nor linear. It calls for an integrated, people - first strategy combining visionary leadership, empathetic culture, sophisticated governance, workforce evolution, and r esponsive market engagement. Organisations embracing this holistic approach will unlock AI’s power not simply as an efficiency tool, but as a capabilit y multiplie r , driving sustained commercial impact and ultimately patient outcomes. Acknowledgements: The author’s sincere thanks go to the countless senior individuals who have contributed to this piece of work, giving their time and energy to unpack this complex subject. They and their companies have remained anonymous throughout the report to preserve confidential ity and they were given no incentive to participate other than to contri b u t e to the state of knowledge around the adoption of this game changing technology in an industry that is not just important to the healthcare system and the patients it serves, but to w h ich we are all so committed Disclaimer: This report was created with the assistance of AI tools. Content has been edited and verified for accuracy by Jonathan Dancer and reviewed by the human subject matter experts who contributed to this work . Whilst all efforts were made to ensure accuracy and the information contained herein does not constitute investment, professional, legal, or regulatory advice and should not be treated as a substitute for independent validation. The authors , contributors and publishers accept no liability for decisions made based on the report .